中药药理与临床2025，Vol.41Issue(10)：62-67,6.
探讨降尿酸方对尿酸性肾病患者脂质代谢的影响
Effect of Jiangniaosuan Prescription on Lipid Metabolism in Patients with Uric Acid Nephropathy
摘要
Abstract
Objective:To predict the mechanism of Jiangniaosuan Prescription in the treatment of uric acid nephropathy based on network pharma-cology and to validate its clinical efficacy and effects on lipid metabolism in patients with uric acid nephropathy through clinical trials.Meth-ods:The core targets and pathways for the efficacy of Jiangniaosuan Prescription were screened by network informatics analysis.A total of 84 patients with uric acid nephropathy with Tanzhuoyuzu(痰浊瘀阻)syndrome who met the inclusion criteria were randomly divided into a con-trol group and an observation group using a double-blind clinical randomized method.The control group received febuxostat(40 mg)plus a placebo for the Jiangniaosuan Prescription,while the observation group received febuxostat(40 mg)plus Jiangniaosuan Granules for a treat-ment period of 12 weeks.Blood lipids(total cholesterol,triglycerides,low-density lipoprotein),blood uric acid,creatinine,glomerular filtra-tion rate,and syndrome scores were assessed before and after treatment.Results:Network pharmacological analysis indicated that lipid and atherosclerosis were the most enriched pathways for Jiangniaosuan Prescription in treating uric acid nephropathy.Clinical trial results showed that after treatment,the effective rate in the observation group was 95%,significantly higher than the 80%in the control group(P<0.05).In the observation group,total cholesterol,triglycerides,and low-density lipoprotein cholesterol showed significant improvement compared to base-line(P<0.05),while the control group only demonstrated statistical significance in triglycerides(P<0.05).The observation group also showed significantly better results than the control group in reducing blood lipids after treatment(P<0.05).Serum uric acid,cystatin C,ser-um creatinine,and glomerular filtration rate in both groups all showed significant differences compared to baseline(P<0.05),with the obser-vation group exhibiting greater reductions in these parameters than the control group(P<0.05).Scores for fatigue,body heaviness,joint pain,scaly skin,edema,tongue coating,and pulse significantly decreased in the observation group compared to baseline(P<0.05).In the control group,scores for joint pain,scaly skin,and edema also significantly decreased compared to baseline(P<0.05),but after treatment,the observation group had significantly lower scores for fatigue,joint pain,scaly skin,edema,and pulse compared to the control group(P<0.05).Conclusion:Jiangniaosuan Prescription effectively improves kidney injury and reduces blood uric acid levels in patients with uric acid ne-phropathy.One of the mechanisms is related to correcting lipid metabolism disorders,consistent with network pharmacological findings that lipid and atherosclerosis are the most enriched pathways for Jiangniaosuan Prescription in treating uric acid nephropathy.关键词
降尿酸方/尿酸性肾病/脂质代谢/网络药理学/临床试验/动脉硬化/肌酐/尿素氮Key words
Jiangniaosuan Prescription/Uric acid nephropathy/Lipid metabolism/Network pharmacology/Clinical trials引用本文复制引用
辛家东,高建东..探讨降尿酸方对尿酸性肾病患者脂质代谢的影响[J].中药药理与临床,2025,41(10):62-67,6.基金项目
上海市科委项目(编号:20Y21901800) （编号:20Y21901800）
国家自然科学基金(编号:82274415). （编号:82274415）
